Trial Profile

Evaluation on Open-Labeled and Dose-Escalation Phase I Clinical Study of Safety and Pharmacokinetics of Recombinant Humanized Bispecific Monoclonal Antibody MBS301 for Injection in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MBS 301 (Primary)
Indications Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Solid tumours
Focus Adverse reactions
Sponsors Beijing Mabworks Biotech

19 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
19 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2024.
09 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com